David Southwell

We have a brand new mechanism for treating cancer with a once a day pill or a series of once a day pills, depending on the dose.

And what we're doing is we're countering a

a syndrome called chromosomal instability, which exists in about 80% of cancers, where in cancer cells, as cells divide, the chromosomes are unstable, whereas in normal cells, they're very orderly and stable.

There's a particular target within chromosomal instability.

When you remove it in a normal cell, it doesn't affect the cell division.

If you remove it in a cancer cell, it disrupts the cancer cell and causes it to die.

I am fortunate to work with the leading researcher in chromosomal instability, who was the founder of our company, and he came out of Sloan Kettering.

And there are several companies that are working on the same mechanism as our lead drug.

We happen to be the furthest along.

And when the company got going, the first company that actually started working with

Kif-18a inhibition started working with this target was Amgen.

And we ended up in licensing their drug very early on.

So we've had the ability to test our own independently developed compound against Amgen's and we owned Amgen's.

So we have no reason to prefer ours over theirs.

It turns out, and Amgen's a stockholder, we know them well.

It turns out that our compound has better efficacy and a better side effect profile than the Amgen one.

So we still do work with the Amgen one, but we're primarily developing our own.

And you know, when I was working in cell therapy, I always was under the impression that small molecule drugs

would never be that effective in treating cancer.

And that is not the case.